ELElizete Aparecida Lomazi

Elizete Aparecida Lomazi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elizete Aparecida Lomazi has a total of 155 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Isolated rectal bleeding in neonates: a scoping review

    by Alexandra Markevich, Júlia G. Botelho, Luana L. Morikawa, Maria Ângela Bellomo Brandão, Elizete A. Lomazi

  • Open Access

    Assessment of abdominal symptoms and intestinal inflammation in children and adolescents with cystic fibrosis without highly effective modulator therapy

    by Gabriel Cezar dos Santos, Lorenna Cristina Montera, Lívia Moreira Genaro, Beatriz Alves Guerra Rodrigues, Raquel Franco Leal, Antonio Fernando Ribeiro, Jose Dirceu Ribeiro, Elizete Aparecida Lomazi

  • Telehealth - A Clinical Practice Initiative in Pediatrics

    by Juliana Helena Zamariola, Maria Angela Bellomo-Brandão, Adriana Gut Lopes Riccetto, Maria Ângela Reis De Góes Monteiro Antonio, Elizete Aparecida Lomazi

  • Open Access

    Upper and small bowel Crohn's disease in Brazilian children: Phenotypic characteristic and surgical risk

    by Jane Oba, Carlos Walter Sobrado, Elizete Aparecida Lomazi, Mariana Deboni, Michela Cynthia da Rocha Marmo, Vanessa Adriana Scheeffer, Silvio da Rocha Carvalho, Adérson Omar Mourão Cintra Damião, Matheus Freitas Cardoso de Azevedo, Carlos Frederico Sparapan Marques, et al.

    Objectives: Upper and small bowel Crohn's disease (U‐SBCD) represents a clinically aggressive phenotype with high complication rates yet remains diagnostically challenging. In low‐ and middle‐income countries (LMICs), limited inflammatory bowel disease (IBD) awareness contributes to diagnostic delays, but their impact on U‐SBCD outcomes remains poorly characterized. We aimed to characterize clinical features, management patterns, and surgical outcomes of pediatric U‐SBCD in Brazil, establishing IBD baseline for future regional comparisons in LMIC setting. Methods: This multicenter retrospective study analyzed 124 pediatric Crohn′s disease (CD) patients (diagnosed < 18 years) from six Brazilian centers according to revised PORTO‐European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) criteria. Patients with U‐SBCD (Paris L4a/L4b, n = 39) were compared to non‐SBCD (L1/L2/L3). Univariate and multivariable analyses assessed demographics, diagnostic delay, disease behavior, growth impairment, and therapeutic outcomes over 18 months follow‐up. The population comprised predominantly African–Brazilian admixture. Results: U‐SBCD patients presented at older age (median 14 vs. 12 years; p = 0.001) with greater height impairment ( p = 0.010) and lower body mass index (BMI)/age z ‐scores (−1.14 vs. −0.44; p = 0.029). Severe weight loss ( z ‐score < −2) conferred 8.3‐fold increased U‐SBCD odds (95% confidence interval [CI]: 2.17–31.66; p = 0.002). Each year of diagnostic delay increased U‐SBCD odds by 22% (95% CI: 1.06–1.39; p = 0.004). U‐SBCD patients required more biologic therapy (97% vs. 75%; p = 0.003) with higher treatment escalation rates (31.6% vs. 21.2%; p = 0.004). Multivariate analysis confirmed U‐SBCD as an independent three‐fold predictor of surgery (OR 3.02; 95% CI: 1.02–8.94; p = 0.046). A 9‐year‐old girl with U‐SBCD died perioperatively. Psychiatric symptoms affected 30% of both groups. Conclusion: In LMIC settings, strengthening medical education is essential to improve early recognition of U‐SBCD and prevent progression to irreversible complications. Notably, the phenotypic pattern observed in our study more closely resembled that reported in Asian pediatric patients than Caucasian cohorts.

  • Open Access

    Cow's milk protein-induced FPIES: Clinical outcomes in severe cases

    by Príscila da Silva Pereira Vasconcelos, Tassiana dos Anjos, Juliana Bellote, Elizete Aparecida Lomazi, Maria Ângela Bellomo-Brandão

  • Open Access

    SEVERE COMPLICATIONS OF BUTTON BATTERY INGESTION IN CHILDREN

    by Vitoria P. Maróstica, Karyne Sumico de Lima Uyeno Jordão, Elizete Aparecida Lomazi, Joaquim Murray Bustorff Silva, Andrea de Melo Alexandre Fraga, Maria Ângela Bellomo-Brandão

    Background: Button battery (BB) ingestion has emerged as a global health concern, particularly among children. Objective: To investigate the clinical outcomes and complications related to BB ingestion among pediatric patients managed at a referral center. Methods: A case series study was conducted between March 2016 and December 2023, including patients under 14 years old diagnosed with BB ingestion. Clinical and radiological evaluations were performed, followed by endoscopic assessment and treatment when required. Data collected included clinical presentation, endoscopic findings, complications, and outcomes. Results: A total of 568 cases of foreign body ingestion were initially reviewed, from which only 16 pediatric patients with confirmed BB ingestion were identified between 2016 and 2023. No cases were documented between 2016 and 2018; however, a substantial increase was observed from 2019 through 2022, with a pronounced surge during 2020-2021 that coincided with the COVID-19 pandemic (P=0.011). Patient ages ranged from 3 months to 5 years, with a median of 3.22 years (1.62-4.55). Endoscopic retrieval was required in seven children (n=7, 43.7%), whereas nine did not undergo endoscopic intervention owing to the extraesophageal location of the BB. Complications were documented in seven patients, including ulceration (n=6; 37.5%), fistulas (n=3, 18.7%), and stenosis (n=3, 18.7%). Conclusion: This study highlights the significant risks of severe complications associated with BB ingestion, even in very young children. A significant increase in severe cases referred to our center during the COVID-19 pandemic underscores the importance of awareness, prevention, and timely medical intervention.

  • Open Access

    Diet quality in Brazilian adolescents with cystic fibrosis

    by Chiara Pascon, Maria Angela Bellomo-Brandão, José Dirceu Ribeiro, Elizete Aparecida Lomazi


  • Open Access

    Food Protein-Induced Enterocolitis Syndrome (FPIES): Clinical Outcomes

    by Priscila Vasconcelos, Tassiana dos Anjos, Juliana Bellote, Elizete Lomazi, Maria Angela Bellomo-Brandao

    Background/Objectives: Food Protein-Induced Enterocolitis Syndrome (FPIES) is a rare and poorly understood condition that primarily affects infants and young children. This study aimed to evaluate the clinical characteristics and outcomes of oral food challenge (OFC) tests in patients diagnosed with FPIES. Methods: A retrospective cohort study was conducted on pediatric patients who underwent OFCs for FPIES at a tertiary health service from January 16, 2018, to June 20, 2024. Both accidental and scheduled in-hospital OFC results were considered. Results: Five patients were included, and 19 OFCs were evaluated. Four patients underwent 4 OFCs each, and one patient underwent 3 OFCs. The mean age of the first symptom onset was 35 days (ranging from 3 days to 2 months). Before the first OFC, the mean duration of the elimination diet was 7 months, and for patients who required additional OFCs, was 11.6 months. Four patients were admitted to the intensive care unit. Two patients were being fed on formula, and three were having mixed feeding. Two patients had a personal and family history of atopy, and one had only a family history of atopy. Two patients had genetic syndromes. All patients developed tolerance to cow’s milk protein within a mean time of 44 months, ranging from 17 to 103 months. The two patients with genetic syndromes had a longer time to develop tolerance. Conclusions: FPIES may require multiple OFCs for diagnosis and management. The time to develop tolerance was longer in patients with genetic syndromes.

  • Open Access

    SMALL INTESTINAL BACTERIAL OVERGROWTH IN PEOPLE WITH CYSTIC FIBROSIS: SYSTEMATIC REVIEW

    by Maria Lidiane Lavor Landim, José Dirceu Ribeiro, Daniela de Souza Paiva Borgli, Danielle Rossana Queiroz Martins Bonilha, Elizete Aparecida Lomazi, Maria de Fátima Correa Pimenta Servidoni

    Background: In patients with cystic fibrosis (pwCF) acid suppression therapy, gastrointestinal dysmotility, and post-operative bowel status, may predispose to the development of small intestinal bacterial overgrowth (SIBO). SIBO may continue to be present in the progression of the disease even on modulators. Breath testing is the most simple, non-invasive and available method for diagnosing SIBO. There are some divergencies over the operational procedures used to carry out and interpret breath tests in pwCF.


  • Intravenous fluids in dehydrated children with acute gastroenteritis: evidence is needed

    by Elizete Aparecida-Lomazi, Marisa da Silva-Laranjeira, Vera M. Santoro-Belangero, Vera L. Sdepanian